Sign Out
Madopar must not be given to patients with known hypersensitivity to levodopa or benserazide or any of the excipients.
Madopar must not be given in conjunction with non-selective monoamine oxidase (MAO) inhibitors. However, selective MAO-B inhibitors, such as selegiline and rasagiline or selective MAO-A inhibitors, such as moclobemide, are not contraindicated. Combination of MAO-A and MAO-B inhibitors is equivalent to non-selective MAO inhibition, and hence this combination should not be given concomitantly with Madopar (see Interactions).
Madopar must not be given to patients with decompensated endocrine, renal (except patients on dialysis) or hepatic function, cardiac disorders, psychiatric diseases with a psychotic component or closed-angle glaucoma.
Madopar must not be given to patients less than 25 years old (skeletal development must be complete).
Madopar must not be given to pregnant women or to women of childbearing potential in the absence of adequate contraception (see Use in Pregnancy & Lactation).
If pregnancy occurs in a woman taking Madopar, the drug must be discontinued (as advised by the prescribing physician).
